Precision BioSciences Inc
NASDAQ:DTIL

Watchlist Manager
Precision BioSciences Inc Logo
Precision BioSciences Inc
NASDAQ:DTIL
Watchlist
Price: 6.86 USD -5.25% Market Closed
Market Cap: 52.6m USD
Have any thoughts about
Precision BioSciences Inc?
Write Note

Precision BioSciences Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Precision BioSciences Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Precision BioSciences Inc
NASDAQ:DTIL
Cash from Financing Activities
$47.4m
CAGR 3-Years
-9%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Precision BioSciences Inc
Glance View

Market Cap
51.3m USD
Industry
Biotechnology

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 198 full-time employees. The company went IPO on 2019-03-28. The company is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The firm's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

DTIL Intrinsic Value
12.31 USD
Undervaluation 44%
Intrinsic Value
Price

See Also

What is Precision BioSciences Inc's Cash from Financing Activities?
Cash from Financing Activities
47.4m USD

Based on the financial report for Sep 30, 2024, Precision BioSciences Inc's Cash from Financing Activities amounts to 47.4m USD.

What is Precision BioSciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-23%

Over the last year, the Cash from Financing Activities growth was 1 751%. The average annual Cash from Financing Activities growth rates for Precision BioSciences Inc have been -9% over the past three years , -23% over the past five years .

Back to Top